K-RAS mutation is observed in a third of IPMN adenomas and its mutation frequency increases with lesion grade (50 % of mutated K-RAS in IPMN borderline and IPMC with invasion) [12, 48]. Here, KRAS is linked to pancreatic intraductal papillary-mucinous neoplasm.